Hitt og þetta 6. júlí 2006

AtheroGenics to Webcast Second Quarter Results Conference Call on July 20, 2006

ATLANTA, GA -- (MARKET WIRE) -- July 06, 2006 -- AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that it expects to release its second quarter 2006 results of operations on Thursday, July 20, 2006, before the U.S. financial markets open.

Company officials will provide a company update and discuss second quarter results via conference call and webcast on Thursday, July 20, 2006, at 9:00 a.m. ET. The conference call may be accessed by dialing 1-877-407-8031 (domestic) or 1-201-689-8031 (international), five minutes prior to the start time. A replay of the call will be available from 11:00 a.m. ET on Thursday, July 20, 2006, until 11:59 p.m. ET on July 27, 2006. Rebroadcast telephone numbers are 1-877-660-6853 (domestic) or 1-201-612-7415 (international), account number 286 and conference ID number 206407. To access the webcast, log on to the Company's Investor Relations Web site http://www.atherogenics.com/investor/q2earnings.html and click on the Webcast Access link. An archived version of this webcast will be available at the same location through October 21, 2006.

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. The Company has two drug development programs currently in the clinic. AtheroGenics' lead compound, AGI-1067, is being evaluated in the pivotal Phase III ARISE clinical trial as an oral therapy for the treatment of atherosclerosis, in collaboration with AstraZeneca. AGI-1096 is a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinical programs in rheumatoid arthritis and asthma utilizing its proprietary vascular protectant® technology. For more information about AtheroGenics, please visit www.atherogenics.com.

AtheroGenics, Inc. Donna L. Glasky Corporate Communications 678-336-2517 investor@atherogenics.com

Investor Relations Lilian Stern Stern Investor Relations, Inc. 212-362-1200 lilian@sternir.com